Trial intelligence / Profile preview

Phase 3 study of selpercatinib versus cabozantinib or vandetanib in kinase inhibitor-naive RET-mutant medullary thyroid cancer

CTR20192718Phase 3Active

Sponsor

Eli Lilly and Company

Start

Feb 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1